South and Central America Anaphylaxis Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Medication Type, Route of Administration, Allergy Type and Distribution Channel

Epinephrine Segment has the Largest Share of Medication Type in the South and Central America Anaphylaxis Treatment Market during 2021-2028

According to a new market research study on “South and Central America Anaphylaxis Treatment Market to 2028 - COVID-19 Impact and Regional Analysis and Forecast by Medication Type, Route of Administration, Allergy Type, and Distribution Channel,” is expected to reach US$ 157.5 million by 2028 from US$ 91.9 million in 2021. The market is estimated to grow at a CAGR of 8% from 2021 to 2028. The report provides trends prevailing in the South and Central America anaphylaxis treatment market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the rising incidence of anaphylaxis and recent approvals of epinephrine are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the poor accessibility to epinephrine auto-injectors in low-income countries.

The outbreak of COVID-19 has severely impacted the flow of medical services in the region. Also, the countries are popular for medical tourism, which is also affected by the pandemic. Brazil, Argentina, Peru, Chile, Uruguay, Colombia are affected by the second wave of corona infection. Among which Brazil has registered the majority of the deaths. As of May 2021, around 411,854 lives have already been lost in Brazil, which is a sign of the second wave of COVID19 infection. It is expected that the region is likely to impose a second lockdown, which will eventually hamper the healthcare industry in the region. Moreover, countries are significantly dependent on the US and European countries for their medical resources. Thus, the region's market has experienced a significant slowdown and is expected to face the same in the following one to two years. Additionally, people in Brazil became more aware of the risk of aggravating asthma or allergic diseases due to COVID-19, along with its treatments, which is leading to boost the growth of the anaphylaxis treatment market in the rest of the world. These factors had a potential impact on the South and Central America anaphylaxis treatment market.

The market for anaphylaxis treatment market is segmented into medication type, route of administration, allergy type, and distribution channel. Based on medication type, the anaphylaxis treatment market is segmented epinephrine, antihistamines, steroids, beta-agonist, and others. In 2020, epinephrine segment accounted for the highest share of the market. The growth of the epinephrine is attributed due to easy access to the epinephrine, rising incidences of allergic reactions and growing government policies to access epinephrine to school-going children. Additionally, the rise in the number of a product launch for generic version epinephrine is key factor responsible for the growth of the market. For instance, in July 2019, Sandoz, a Novartis AG division, has launched its generic pre-filled Symjepi epinephrine shots across the country.

Amneal Pharmaceuticals Inc. Mylan N.V. Abbott, Pfizer Inc. Glaxosmithkline Plc. Merck and Co. Inc. Teva Pharmaceutical Industries Ltd. and ALK-ABELLó are among the leading companies in the South and Central America anaphylaxis treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in December 2020, GSK Consumer Healthcare launched Otrivin Breathe clean, a saline wash with the moisturizing benefit of natural glycerin. The daily usage of the nasal spray washes out the allergens, pollutants, and debris that are trapped in the nasal passage, helping in the removal of allergy symptoms, and thus maintaining nasal hygiene.

The report segments the South and Central America Anaphylaxis Treatment market as follows:

By Medication Type

• Epinephrine
• Antihistamines
• Steroids
• Beta-Agonist
• Others

By Route of Administration

• Parenteral
• Oral
• Others

By Allergy Type

• Food Allergy
• Medications
• Insect Stings
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

By Country

• South and Central America
• Brazil
• Argentina
• Rest of South and Central America

Reasons to buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America anaphylaxis treatment market
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the South and Central America anaphylaxis treatment market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth South and Central America market trends and outlook coupled with the factors driving the anaphylaxis treatment market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution